A Phase I/II Study of Tiragolumab and Atezolizumab for Children and Adults with Recurrent or Persistent SMARCB1- or SMARCA4-Deficient Tumors

Share

Full Title

A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (PEPN2121) (CIRB)

Purpose

Researchers in this study are assessing how tiragolumab and atezolizumab work when given to children and adults with tumors that have come back or continued to grow despite treatment and are lacking the SMARCB1 or SMARCA4 genes. Cancers lacking these genes are more aggressive and harder to treat successfully.

Tiragolumab and atezolizumab are immunotherapy drugs that boost the power of the immune system to fight cancer and may interfere with the ability of tumor cells to grow and spread. These medications are given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have a tumor that is lacking the SMARCB1 or SMARCA4 genes and has come back or continued to grow despite treatment. Examples includes renal medullary carcinoma, rhabdoid tumors, poorly differentiated chordoma, and epithelioid sarcoma.
  • The serious side effects of previous treatments must go away before the study therapy is given.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 1 year and older.

Contact

For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.

Protocol

22-357

Phase

I/II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators